Comprehensive molecular analysis of 333 primary prostate carcinomas
Seven subtypes defined by ETS fusions or mutations in SPOP, FOXA1, and IDH1
Substantial epigenetic heterogeneity, including a hypermethylated IDH1 mutant subset
Presumed actionable lesions in the PI3K, MAPK, and DNA repair pathways